Clinical Data for the Use of Cannabis-Based Treatments: A Comprehensive Review of the Literature
Autor: | Renee D Pitt, Sarah E Yost, Meryl Biksacky, Whitney Mortensen, Sophia Entringer, Shannon Inglet, Anh Lian, Bradly Winter |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
Multiple Sclerosis Vomiting Nabiximols Pain Medical Marijuana 03 medical and health sciences Drug Utilization Review 0302 clinical medicine medicine Humans Pharmacology (medical) 030212 general & internal medicine Psychiatry Tetrahydrocannabinol Clinical Trials as Topic biology business.industry Nausea biology.organism_classification Nabilone Practice Guidelines as Topic Medical cannabis Dronabinol Cannabis business Cannabidiol 030217 neurology & neurosurgery medicine.drug |
Zdroj: | Annals of Pharmacotherapy. 54:1109-1143 |
ISSN: | 1542-6270 1060-0280 |
Popis: | Objective: To compile and synthesize the available literature describing medical cannabis use across various disease states. Data Sources: PubMed, EBSCO, and Google Scholar searches were conducted using MeSH and/or keywords. Study Selection and Data Extraction: Studies were included if they described the use of cannabis-based products and medications in the treatment of a predefined list of disease states in humans and were published in English. The extraction period had no historical limit and spanned through April 2019. Data Synthesis: Evidence was compiled and summarized for the following medical conditions: Alzheimer disease, amyotrophic lateral sclerosis, autism, cancer and cancer-associated adverse effects, seizure disorders, human immunodeficiency virus, inflammatory bowel disease, multiple sclerosis (MS), nausea, pain, posttraumatic stress disorder, and hospice care. Relevance to Patient Care and Clinical Practice: Based on identified data, the most robust evidence suggests that medical cannabis may be effective in the treatment of chemotherapy-induced nausea and vomiting, seizure disorders, MS-related spasticity, and pain (excluding diabetic neuropathy). Overall, the evidence is inconsistent and generally limited by poor quality. The large variation in cannabis-based products evaluated in studies limits the ability to make direct comparisons. Regardless of the product, a gradual dose titration was utilized in most studies. Cannabis-based therapies were typically well tolerated, with the most common adverse effects being dizziness, somnolence, dry mouth, nausea, and euphoria. Conclusions: As more states authorize medical cannabis use, there is an increasing need for high-quality clinical evidence describing its efficacy and safety. This review is intended to serve as a reference for clinicians, so that the risks and realistic benefits of medical cannabis are better understood. |
Databáze: | OpenAIRE |
Externí odkaz: |